Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,749 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report.
Jo JC, Kim SJ, Lee HS, Eom HS, Lee SI, Park Y, Lee JO, Lee Y, Yhim HY, Yang DH, Byun JM, Kang HJ, Kim HJ, Shin HJ, Yoo KH, Suh C; and Consortium for Improving Survival of Lymphoma (CISL). Jo JC, et al. Ann Hematol. 2020 Feb;99(2):223-228. doi: 10.1007/s00277-019-03803-x. Epub 2019 Dec 18. Ann Hematol. 2020. PMID: 31853704
The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study).
Jo JC, Lee HS, Kim K, Lee JJ, Yoon SS, Bang SM, Kim JS, Eom HS, Yoon DH, Lee Y, Shin HJ, Park Y, Lee WS, Do YR, Mun YC, Lee MH, Kim HJ, Kim SH, Kim MK, Lim SN, Cho SH, Park SK, Yi JH, Lee JH, Kim J, Min CK; Korean Multiple Myeloma Working Party (KMMWP). Jo JC, et al. Ann Hematol. 2020 Feb;99(2):309-319. doi: 10.1007/s00277-019-03904-7. Epub 2019 Dec 23. Ann Hematol. 2020. PMID: 31872360 Clinical Trial.
Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
Lee HS, Kim K, Lee JJ, Yoon SS, Bang SM, Kim JS, Eom HS, Yoon DH, Lee Y, Shin HJ, Park Y, Jo JC, Lee WS, Do YR, Mun YC, Lee MH, Kim HJ, Kim SH, Kim MK, Lim SN, Park SK, Yi JH, Lee JH, Min CK; Korean Multiple Myeloma Working Party (KMMWP). Lee HS, et al. Int J Hematol. 2021 Jan;113(1):81-91. doi: 10.1007/s12185-020-02988-6. Epub 2020 Sep 5. Int J Hematol. 2021. PMID: 32889695
Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL).
Jo JC, Kim JS, Lee JH, Lee JH, Lim SN, Lee SM, Yoon SS, Kim IH, Bae SH, Lee YJ, Choi Y, Lee WS. Jo JC, et al. Among authors: lee sm, lee ws, lee jh, lee yj. Bone Marrow Transplant. 2020 Jul;55(7):1466-1468. doi: 10.1038/s41409-020-0908-3. Epub 2020 Apr 17. Bone Marrow Transplant. 2020. PMID: 32303709 No abstract available.
Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma.
Lee YJ, Moon JH, Sohn SK, Kim SJ, Jung SH, Lee JJ, Jo JC, Shin HJ, Lee WS, Lee JH, Bae SH, Kim MK, Lee HS, Kim K, Min CK; Korean Multiple Myeloma Working Party. Lee YJ, et al. Among authors: lee hs, lee ws, lee jh, lee jj. Bone Marrow Transplant. 2019 Dec;54(12):2051-2059. doi: 10.1038/s41409-019-0629-7. Epub 2019 Jul 29. Bone Marrow Transplant. 2019. PMID: 31358918 Free PMC article.
Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT.
Cho HJ, Jung SH, Jo JC, Lee YJ, Yoon SE, Park SS, Kim DY, Shin HJ, Mun YC, Yi JH, Kim HJ, Kim DJ, Lee HS, Bae SH, Hong CM, Jeong SY, Min JJ, Sohn SK, Min CK, Kim K, Lee JJ, Moon JH; Korean Multiple Myeloma Working Party. Cho HJ, et al. Among authors: lee hs, lee yj, lee jj. Blood Cancer J. 2021 Dec 1;11(12):190. doi: 10.1038/s41408-021-00577-2. Blood Cancer J. 2021. PMID: 34853295 Free PMC article.
8,749 results